

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



10/536950

(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/050101 A2

(51) International Patent Classification⁷: A61K 33/04, (74) Agents: LEIDESCHER, Thomas et al.; Zimmermann & Partner, P.O. Box 330 920, 80069 Munich (DE).

(21) International Application Number:

(22) International Filing Date: 1 December 2003 (01.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 102 55 861.2 29 November 2002 (29.11.2002) DE
 60/430,367 3 December 2002 (03.12.2002) US
 103 05 138.4 7 February 2003 (07.02.2003) DE
 60/446,246 11 February 2003 (11.02.2003) US

(71) Applicant (for all designated States except US): AXXIMA PHARMACEUTICALS AG [DE/DE]; Max-Leb-sche-Platz 32, 81377 Munich (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HERGET, Thomas [DE/DE]; Georgenstrasse 29, 82152 Planegg (DE). KLEBL, Bert [DE/DE]; Imhoffstrasse 16, 82294 Günzlhofen (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: FORMULATIONS USEFUL AGAINST HEPATITIS C VIRUS INFECTIONS



RA induces (in the presence of Selenium) expression of GI-GPx and down-regulation of HCV protein NS5a.

(57) **Abstract:** The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and/or substances, to methods for preventing HCV infections as well use of the compounds and/or substances for the preparation of compositions useful for the prophylaxis and/or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D₃ and retinoids, like all trans retinoic acid and salts thereof, C₁ - C alkyl amide of all trans retinoic acid and salts thereof, C₁ - C₁₀ alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C₁ - C₁₀ alkyl amide of 9-cis retinoic acid and salts thereof, C₁ - C₁₀ alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2 (5,6,7,8-tetrahydro-5,5,8,8-tetrahydro-2-naphthalenyl-1-propenyl) benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro-5,5,8,8-tetrahydro-2-naphthalenyl] carboxamido) benzoic acid (AM-580), N-(4-hydroxyphenyl) retinamide (4-HPR), and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).